少年人群接种乙肝疫苗后七年随访观察  

Follow up for seven years in adolescents vaccinated with plasma-derived HBV vaccine

作　　者：郑菊梅[1] 孟秀园 章明太[1] 刘克洲[1] 金建华[1] 张秀芝[1] 周绍聪[1] 

机构地区：[1]卫生部兰州生物制品研究所,浙江医科大学传染病研究所

出　　处：《微生物学免疫学进展》1995年第4期193-196,共4页Progress In Microbiology and Immunology

摘　　要：对７９名ＨＢＶ标志阴性少年人群，以乙肝疫苗１０μｇ×３的免疫剂量和０、１、２月的免疫程序进行接种，对其抗－ＨＢｓ免疫应答和临床保护效果作了为期７年的定人随访。结果表明，抗－ＨＢｓ阳转率在免后三个月时为１００％，均值为３０８４ＭＩＵ／ｍｌ。至免后８４个月时疫苗接受者中仍有５５．７％的抗－ＨＢｓ水平≥１０ＭＩＵ／ｍｌ。６例检出抗－ＨＢｓ，其中５例的抗－ＨＢｓ持续处于高水平。全部观察对象无一例检出ＨＢｓＡｇ或发生临床肝炎。少年接种乙肝血源疫苗至少７年内可具有保护性抗体。故在此期内不需加强免疫。Seventy-nine adolescents negative for HBV serologic markers have been received three doses of 10μg HBV vaccine derived from human plasma by a schedule of 0、1、2 month,and subsequently follow-up with immune response and clinical protection annually for seven years. The results showed that the positive rate of anti-HBs was 100% at three months with GMTs 3084mIU/ml level. Among these vaccinees ,six have developed the anti-HBc,Five kept the anti－HBs at high level persistently. None of them developed detectable HBsAg or clinical hepatitis. Immunization of adolescents with plasma-derived HBV vaccine has proved here to have protective immune activity that can prevent or modify primary infection for at least seven years,booster immunization is not necessary during this period.

关 键 词：乙型肝炎疫苗 免疫接种 免疫持久性 少年 

分 类 号：R512.620.3[医药卫生—内科学]